Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2026

Balance Sheet Related Disclosures [Abstract]

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):


		June 30,				December 31,
		2026				2025
Accrued compensation expenses		$	13,300			$	14,841
Accrued professional & consulting expenses			1,047				1,253
Accrued research and development expenses			—				1,355
Accrued revenue allowances			87,749				65,462
Accrued other			6,931				6,920
Total accrued expenses		$	109,027			$	89,831

Schedule of Inventory

Inventory consists of the following (in thousands):


		June 30,				December 31,
		2026				2025
Finished goods		$	1,496			$	1,457
Raw materials			6,217				4,061
Total inventory, current			7,713				5,518
Raw materials, non-current			21,827				20,732
Total inventory		$	29,540			$	26,250

Raw materials consist of materials, including active pharmaceutical ingredients, to be consumed in the production of inventory related to FDA-approved products. Inventory that is used for clinical development purposes is expensed to research and development expense when consumed. Inventory, noncurrent includes inventory expected to remain on-hand beyond one year from the balance sheet dates presented.